Financial Analysis: Whitehawk Therapeutics and Vincerx Pharma

Comparing the performance and outlook of two small-cap medical companies

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Vincerx Pharma (NASDAQ:VINC) and Whitehawk Therapeutics (NASDAQ:WHWK) are both small-cap medical companies, but which one is the superior business? This analysis compares the two companies based on factors like earnings, analyst recommendations, institutional ownership, profitability, valuation, and risk.

Why it matters

Understanding the relative strengths and weaknesses of these two small-cap biotech firms can help investors make more informed decisions about where to allocate their capital in the healthcare sector.

The details

The analysis looks at metrics like net margins, return on equity, return on assets, analyst recommendations, institutional ownership, share price volatility, revenue, earnings per share, and valuation ratios. Overall, the data suggests that Whitehawk Therapeutics outperforms Vincerx Pharma on most of the key factors compared.

  • The analysis is based on data reported as of February 28, 2026.

The players

Vincerx Pharma

A clinical-stage biopharmaceutical company researching and developing therapies to treat cancer.

Whitehawk Therapeutics

A small-cap medical company focused on developing precision therapies for genetically defined cancers.

Got photos? Submit your photos here. ›

The takeaway

This analysis provides a comprehensive look at the relative strengths and weaknesses of Vincerx Pharma and Whitehawk Therapeutics, highlighting key factors investors should consider when evaluating these two small-cap biotech firms.